BlackRock
INKT icon

BlackRock’s MiNK Therapeutics INKT Stock Holding History

BlackRock’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156K Buy
13,382
+7,179
+116% +$83.6K ﹤0.01% 4889
2026
Q1 		$65.3K Hold
6,203
– – ﹤0.01% 5060
2025
Q4 		$69.2K Sell
6,203
-95
-2% -$1.23K ﹤0.01% 4981
2025
Q3 		$88.2K Sell
6,298
-1,123
-15% -$18K ﹤0.01% 4858
2025
Q2 		$54.8K Sell
7,421
-1,357
-15% -$10.2K ﹤0.01% 4972
2025
Q1 		$75.8K Sell
8,778
-50
-0.6% -$445 ﹤0.01% 4828
2024
Q4 		$61.5K Buy
8,828
+15
+0.2% +$102 ﹤0.01% 4897
2024
Q3 		$66.1K Buy
8,813
+93
+1% +$789 ﹤0.01% 4749
2024
Q2 		$82.8K Buy
8,720
+1,105
+15% +$10.8K ﹤0.01% 4747
2024
Q1 		$69.2K Sell
7,615
-31
-0.4% -$288 ﹤0.01% 4811
2023
Q4 		$81.8K Sell
7,646
-404
-5% -$4.22K ﹤0.01% 4864
2023
Q3 		$88.5K Sell
8,050
-153
-2% -$2.49K ﹤0.01% 4880
2023
Q2 		$172K Buy
8,203
+7,117
+655% +$143K ﹤0.01% 4771
2023
Q1 		$20.6K Buy
1,086
+36
+3% +$779 ﹤0.01% 5254
2022
Q4 		$27.4K Buy
1,050
+49
+5% +$1.15K ﹤0.01% 5342
2022
Q3 		$21K Buy
1,001
+337
+51% +$6.64K ﹤0.01% 5502
2022
Q2 		$10K Sell
664
-1,100
-62% -$20.7K ﹤0.01% 5625
2022
Q1 		$40K Buy
1,764
+724
+70% +$21.7K ﹤0.01% 5457
2021
Q4 		$46K Buy
+1,040
New +$124K ﹤0.01% 5416

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $151M AUM

BlackRock's INKT Position: Q2 2026 in Review

BlackRock increased its MiNK Therapeutics (INKT) stake by 116% in Q2 2026, buying an estimated $83.6K and bringing the position to 13,382 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #4889.

BlackRock first reported a position in INKT in Q4 2021 and has held it in 19 quarters since. The position peaked at $172K in Q2 2023. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • BlackRock held 13,382 shares of MiNK Therapeutics worth $156K as of Q2 2026.
  • BlackRock bought 7,179 MiNK Therapeutics shares in Q2 2026, an estimated $83.6K.
  • MiNK Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4889 holding.
  • BlackRock first reported a position in MiNK Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • BlackRock's MiNK Therapeutics position peaked at $172K in Q2 2023.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.